Biotechnology moves fast. Between clinical trials, FDA milestones, funding rounds, and the daily grind of moving science from the lab to the market, the last thing most biotech founders have time for is figuring out how to get covered in STAT News or FierceBiotech.
That is where we come in.
AceIt Agency is a biotech PR agency that works with biotechnology companies at every stage, from pre-clinical through commercialization, to build the kind of media presence that earns attention from journalists, investors, and partners who matter.
We sit at the intersection of healthcare communications and technology PR. That is not a coincidence. Biotech is not purely science. It is not purely tech. It is both, and it demands a communications partner who understands the business behind the breakthroughs.
We secure placements in the publications your enterprise buyers, investors, and partners actually read.
Most PR agencies can write a press release. Very few understand why a Phase II readout matters more to your investors than a product launch, or why a placement in Endpoints News will move your stock more than a hit in a lifestyle magazine.
Biotech public relations operates in a world of regulatory complexity, scientific nuance, and audiences who can spot fluff from a mile away. Your stakeholders, whether they are venture capital firms, key opinion leaders, potential partners, or patients following your clinical pipeline, expect precision.
Here is what that means for how we work:
We learn your science. Not at a surface level. We go deep enough to understand the mechanism of action, the competitive landscape, and the unmet need your work addresses. Whether you are developing gene therapies, advancing precision medicine, working on mRNA-based platforms, or building diagnostic tools, we learn the language your audience speaks.
We build narratives around milestones that matter. In biotech, timing is everything. An IND filing, a Phase I/II trial initiation, a Series B raise, a key regulatory milestone, or a partnership announcement, these are the moments that shape perception. We create communications strategies around those moments so the right people hear about them at the right time.
We target the publications your stakeholders actually read. Biotech investors are not scrolling general business outlets for deal flow. They are reading BioPharma Dive, GEN, BioSpace, MedCity News, Evaluate, and Nature Biotechnology. We know these outlets, their editorial calendars, and the journalists who cover your therapeutic area.
Earned media is the foundation of credibility in biotech. When a journalist at STAT News or Endpoints News covers your company based on the strength of your story, not because you paid for placement, it sends a signal to the entire ecosystem: this company is worth watching.
We develop targeted media outreach strategies built around your news cycle. That includes crafting press releases with scientific rigor, pitching story angles to beat reporters covering your space, and preparing your leadership team with media training so they are ready when the interview request comes in.
The biotech funding environment is competitive. Whether you are closing a seed round, raising a Series A, preparing for an IPO, or communicating results that affect your public valuation, PR plays a direct role in shaping investor perception.
We help biotech companies build an investor relations communications layer that includes pitch deck messaging, roadshow preparation, funding announcement press releases, and ongoing visibility in the financial and trade media that VCs and institutional investors follow.
Your CEO has a vision. Your CSO has data. We help them share both.
Through bylined articles, contributed commentary, speaking opportunities at scientific conferences like BIO International, JPM Healthcare Conference, and ASCO, and strategic LinkedIn positioning, we turn your leadership team into recognized voices in biotech.
Scientific storytelling is not about dumbing down the science. It is about finding the human angle, the patient story, the problem your technology solves, and building a narrative that resonates with both scientific and lay audiences.
For biotech companies moving from stealth mode to public visibility, or transitioning from pre-clinical to clinical-stage, corporate positioning is everything. How you introduce yourself to the market defines how you will be perceived for years.
We develop messaging frameworks, brand positioning strategies, and corporate narratives that hold up under scrutiny from investors, journalists, regulators, and competitors alike.
Biotech companies face unique crisis scenarios: a clinical trial hold, an unexpected safety signal, negative analyst coverage, leadership transitions, or regulatory pushback. These situations require fast, clear, and scientifically literate communications.
We provide crisis communications counsel and rapid response support to protect your reputation when the stakes are highest.
Your website is often the first thing a potential investor, partner, or journalist looks at after hearing about your company. We help biotech companies build a digital presence that reflects the quality of their science, including website messaging, blog content, white papers, and social media strategy that reinforces your credibility across channels.
We work with biotechnology companies across therapeutic areas and development stages:
Companies developing small molecule therapeutics, biologics, biosimilars, antibody therapies, CAR-T cell therapies, gene and cell therapies, mRNA platforms, and regenerative medicine technologies.
Diagnostics and companion diagnostics companies building tools for personalized medicine, from liquid biopsy platforms to genomics-based screening.
Medical device companies operating at the intersection of biotech and engineering, including biomarker-driven devices, wearable health monitors, and surgical innovation.
Biotech-adjacent organizations including CROs (contract research organizations), CDMOs, biotech-focused venture capital firms, and life sciences accelerators.
Whether you are a two-person startup working out of a shared lab or a clinical-stage company preparing for your first FDA submission, we scale our approach to where you are right now and where you need to go.
Every engagement starts with one question: What is your desired business outcome?
It is a simple question, but the answer shapes everything. For some biotech companies, the goal is investor visibility ahead of a raise. For others, it is building brand awareness before a product launch. For some, it is establishing thought leadership in a competitive therapeutic area.
We do not run from the fact that biotech PR requires patience. This is not consumer goods, where a single viral moment can change a brand overnight. Biotech communications is a long game. It is about consistent, strategic visibility that compounds over time.
Here is what our process looks like:
We understand regulated industries. Our team works across healthcare, technology, and the complex space where they intersect. We know how to communicate within the boundaries of what you can and cannot say publicly as a biotech company, especially around clinical data, regulatory filings, and pre-approval claims.
We bring a media network that reaches beyond trade. Yes, we can get you in FierceBiotech and GEN. But we also have relationships across Forbes, TechCrunch, Entrepreneur, USA Today, and other major outlets. When your story has a broader angle, like a patient impact story, a founder profile, or a funding milestone, we know how to place it where it gets the widest, most relevant reach.
We are outcome-driven. We measure success by what it does for your business, not by clip counts. A single placement that brings in three investor meetings is worth more than twenty placements nobody reads. Our approach, what we call AceIt Outcome Marketing, keeps us focused on results that move the needle.
We are built for companies that move fast. Biotech does not wait. Trial results drop, funding windows open, regulatory decisions happen. You need a PR partner that can respond in hours, not weeks. We are structured for speed without sacrificing strategic thinking.
A biotech PR agency helps biotechnology companies build visibility and credibility through strategic communications. This includes media relations (getting coverage in trade and national outlets), investor communications (supporting fundraising with PR), thought leadership (positioning executives as industry experts), crisis communications, and corporate positioning. The goal is to shape how journalists, investors, partners, regulators, and the broader market perceive your company and your science.
Most biotech companies benefit from bringing on a PR partner 3 to 6 months before a major milestone: a funding announcement, a clinical trial initiation, an FDA filing, a product launch, or a conference presentation. That lead time allows for strategy development, media relationship building, and message refinement. However, some companies in stealth mode also benefit from early PR planning to prepare their public debut.
Healthcare PR often focuses on hospital systems, health insurance, wellness brands, or consumer health products. Biotech PR is more specialized: it involves communicating complex science to audiences who include institutional investors, analysts, scientists, KOLs, and regulatory stakeholders. The language is more technical, the approval cycles are longer, and the sensitivity around clinical data and regulatory milestones is much higher.
Yes. While PR and investor relations are distinct disciplines, they overlap significantly in biotech. A well-placed feature in STAT News or BioPharma Dive can directly influence investor interest. PR supports capital raises by building brand credibility, generating media visibility around funding milestones, and helping leadership teams prepare for investor-facing communications including roadshows and pitch presentations.
The most impactful outlets for biotech media relations include FierceBiotech, STAT News, Endpoints News, BioPharma Dive, BioSpace, GEN (Genetic Engineering & Biotechnology News), MedCity News, Nature Biotechnology, Science, and Evaluate. For broader visibility, outlets like Forbes, Entrepreneur, USA Today, Wall Street Journal, Financial Times, and TechCrunch are valuable when the story angle extends beyond the industry.
Pricing varies based on scope, but most biotech PR engagements range from a monthly retainer model that includes ongoing media relations, content development, and strategic counsel, to project-based work around specific milestones like a launch or funding round. We offer flexible structures that scale with your company’s stage and budget. [Contact us for a custom quote.]
Your science deserves to be seen by the people who can help it reach patients. Whether you are raising your next round, preparing for a clinical milestone, or simply ready to step out of stealth mode and into the spotlight, we are here to help you tell that story.
